Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Osteosarcoma 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Peripheral Blood Stem Cell Transplantation 12Mycophenolic Acid 11Cyclosporine 11fludarabine phosphate 9Cyclophosphamide 9Whole-Body Irradiation 7Tacrolimus 6Radiotherapy 6Methylprednisolone 6Filgrastim 6Methotrexate 5Etoposide 5Antilymphocyte Serum 5Therapeutics 4Busulfan 4Melphalan 3Cord Blood Stem Cell Transplantation 3Rituximab 2Prednisone 2Polymerase Chain Reaction 2Ondansetron 2Itraconazole 2Flow Cytometry 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2trametinib 1thymoglobulin 1sargramostim 1ontuxizumab 1obatoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × trametinib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡